EUVIMEDEUVIMED entdecken
Crossref

Perioperative Outcomes of Neoadjuvant Therapy in Resectable Lung Cancer Patients With Endobronchial Disease in the Era of Personalized Medicine

Joseph Seitlinger, Devangi Patel, Andrew Meng, Luciano Bulgarelli-Maqueda, Jonathan Cools-Lartigue, Christian Sirois, Lorenzo Ferri, Jonathan Spicer, Sara Najmeh

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2024.10.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Joseph Seitlinger und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic and Upper Gastrointestinal Surgery, Montreal General Hospital, McGill University Health Center, Montreal, Quebec, Canada; Thorac…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Lung Neoplasms, Precision Medicine. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lung cancer remains the leading cause of cancer-related deaths worldwide. Recent studies have highlighted the benefit of neo-adjuvant therapies in the treatment of resectable stage IB to IIIA cases which will likely increase the use of neoadjuvant therapies (NAT) across multiple stages, both earlier and later. This includes the combination of chemotherapy and immunotherapy as well as the more widespread use of targeted therapies with or without the addition of radiation. This heterogenous group of resectable tumors includes proximal tumors with different levels of endobronchial involvement and secondary distal atelectasis and sometimes superimposed infections which adds a level of concern and complexity when using NAT. In this study, we evaluate the prevalence of endobronchial lesions in patients treated with NAT, as well as the rate of associated complications. PATIENTS AND METHODS: Data was obtained from a prospectively maintained thoracic surgery database, the Thoracic Oncology Clinical Database and Biobank. Patients with proven clinical stage II-III NSCLC that underwent resection within the Division of Thoracic Surgery at the McGill University Health Centre (Montreal, QC, Canada) from January 2015 to December 2020 were included. Chest computed tomography scans prior to neoadjuvant therapy were reviewed by 2 senior thoracic surgeons to establish the presence of an endobronchial tumor lesion. The presence of an endobronchial lesion was defined by a tumoral lesion obstructing a bronchus or several bronchi AND responsible for lung atelectasis distally (with at least 1 occluded segment). Treatment-related and postoperative complications were collected retrospectively by reviewing patient charts. RESULTS: Overall, 110 patients met the inclusion criteria, of which 37/110 patients had endobronchial lesions before starting neoadjuvant therapy (33.6%). These patients had a higher rate of global complications 23/37 (62.2%) during neoadjuvant treatment compared to patients without obstruction 30/73 (41.1%) (P = .04). There was no difference in terms of severity of complications between the 2 groups (P = .34). The group with endobronchial lesions was found to have an increased rate of pulmonary complications, of which there were none in the other group (5/37, 13.5% vs. 0/73, 0%, P = .004). There were 2 cases of patients requiring urgent surgeries before completing NAT due to pulmonary complications in the endobronchial lesion group (2/37, 5.4%) and none in the group without obstruction. CONCLUSION: Patients who are treated with NAT for locally advanced resectable lung cancer usually have larger tumors, where it is not uncommon to encounter endobronchial lesions responsible for downstream obstruction. In this study, the prevalence of endobronchial lesions was found to be 1 third of the patients undergoing NAT. The presence of endobronchial disease was associated with increased risk of complications during neoadjuvant treatment. These complications presented more frequently as pulmonary complications and required in some cases urgent surgical resection. Therefore, patients with endobronchial tumors undergoing NAT should be identified as a high-risk group and would likely benefit from closer clinical follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyLung NeoplasmsPrecision MedicineHumansMaleFemaleAgedMiddle AgedRetrospective StudiesPneumonectomyCarcinoma, Non-Small-Cell LungPostoperative ComplicationsTreatment OutcomeFollow-Up StudiesNeoplasm Staging

Stichwörter der Autor:innen

Endobronchial lesionLung CancerMultimodality therapyNeoadjuvant treatmentPerioperative complications

Autor:innen und Institutionen

  • Division of Thoracic and Upper Gastrointestinal Surgery, Montreal General Hospital, McGill University Health Center, Montreal, Quebec, Canada; Thoracic surgery department, Nancy University Hospital, Nancy, France.
  • Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
  • Division of Thoracic and Upper Gastrointestinal Surgery, Montreal General Hospital, McGill University Health Center, Montreal, Quebec, Canada.
  • Division of Thoracic and Upper Gastrointestinal Surgery, Montreal General Hospital, McGill University Health Center, Montreal, Quebec, Canada. Electronic address: sara.najmeh@mcgill.ca.

Zitieren

APA

Seitlinger, J., Patel, D., Meng, A., Bulgarelli-Maqueda, L., Cools-Lartigue, J., Sirois, C., Ferri, L., Spicer, J., & Najmeh, S. (2025). Perioperative Outcomes of Neoadjuvant Therapy in Resectable Lung Cancer Patients With Endobronchial Disease in the Era of Personalized Medicine. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.10.003

Vancouver

Seitlinger J, Patel D, Meng A, Bulgarelli-Maqueda L, Cools-Lartigue J, Sirois C, et al. Perioperative Outcomes of Neoadjuvant Therapy in Resectable Lung Cancer Patients With Endobronchial Disease in the Era of Personalized Medicine. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2024.10.003

BibTeX
@article{Seitlinger2025,
  author = {Seitlinger, Joseph and Patel, Devangi and Meng, Andrew and Bulgarelli-Maqueda, Luciano and Cools-Lartigue, Jonathan and Sirois, Christian and Ferri, Lorenzo and Spicer, Jonathan and Najmeh, Sara},
  title = {Perioperative Outcomes of Neoadjuvant Therapy in Resectable Lung Cancer Patients With Endobronchial Disease in the Era of Personalized Medicine},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2024.10.003}
}
Kostenlos starten →